 CONSHOHOCKEN, Pa., Nov. 05, 2020 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The Company also announced its third quarter 2020 financial results and highlights. 